<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231016059737N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-20</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Tdcs in frontotemporal dementia</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Transcranial Direct Current Stimulation (TDCS) effect on the cognitive symptoms of patients with frontotemporal dementia: a randomized double blind trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73202</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Block randomization
A randomized block design is a design, in which experimental units are first organized into homogeneous blocks and then the treatments are assigned at random to these units within these blocks. The main advantage of this design is, if done properly, it provides more precise results, Blinding description: The control and intervention group patients are both blinded and none of them are told which group they are in. The intervention patients are placed with the tdcs device and have electrical activity, but for the control group, the device is placed but the electric current is not active.
The clinical caregiver who is responsible for placing tdcs on the patients is also blind. The settings of the device are applied by the relevant doctor.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Frontotemporal dementia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:After confirming the diagnosis of the patients, the MMSE Mini-Mental State Examination test is taken from the people. The short mental state test is a test to evaluate the quality of consciousness with the diagnosis and screening of dementia, the maximum score of which is 30. People whose MMSE score is higher than 20 will enter the study. Patients are treated with anodal tDCS. In the anodal tDCS group, anodal stimulation depolarizes neurons and increases the probability of action potentials. Stimulation is done unilaterally on the dorsolateral prefrontal cortex and tDCS will be done for the patients during 5 consecutive days, before tDCS, neuropsychiatric tests including frontal assessment battery,  trail making test , verbal fluency (PFT), Picture naming task (PNT), Go no-GO task (GGT),Brief test  and NPI (Neuropsychiatric inventory) are performed for patients immediately after tDCS and again 1 month after tDCS. Patients will undergo a second round 2 months after the first tDCS, and those who received anodal at the beginning will now receive sham and vice versa. Intervention 2: Control group: After confirming the diagnosis of the patients, the MMSE Mental State Examination-Mini test is taken from the people. The short MMSE mental state test is a test to evaluate the quality of consciousness with the diagnosis and screening of dementia, the maximum score of which is 30. People whose MMSE score is above 20 are included in the study. Patients are treated with anodal tDCS and sham tDCS. The sham group is a general term to indicate a passive form of stimulation (eg, very brief or weak) that is used in research to control the placebo effect. Stimulation is performed unilaterally on the dorsolateral prefrontal cortex and tDCS will be performed for 5 consecutive days for the patients. Before performing tDCS, neuropsychiatric tests including frontal battery assessment,rail makimg test ,phonemic verbal fluency (PFT) ), Picture naming task (PNT), Go no-GO task (GGT), Brief test and NPI (Neuropsychiatric inventory) are performed for patients immediately after tDCS and again 1 month after tDCS. Patients will undergo a second round 2 months after the first tDCS, and those who received anodal at the beginning will now receive sham and vice versa.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahid Reza Ostovan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahhari Clinic, Namazi sq, Zand St.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۳۴۸۷۱۴۷۳۷</zip>
        <telephone>+98 71 3612 1065</telephone>
        <email>ostovanv@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahid Reza Ostovan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahhari Clinic, Namazi sq, Zand St.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۳۴۸۷۱۴۷۳۷</zip>
        <telephone>+98 71 3612 1065</telephone>
        <email>ostovanv@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Frontotemporal dementia
MMSE more than 11</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Psychiatric or neurologic disorders except FTD
Epilepsy
MDD
Scalp or skull lesions
Contraindications for mri and tdcs like such as ferromagnetic devices in skull</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G31.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Frontotemporal dementia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:After confirming the diagnosis of the patients, the MMSE Mini-Mental State Examination test is taken from the people. The short mental state test is a test to evaluate the quality of consciousness with the diagnosis and screening of dementia, the maximum score of which is 30. People whose MMSE score is higher than 20 will enter the study. Patients are treated with anodal tDCS. In the anodal tDCS group, anodal stimulation depolarizes neurons and increases the probability of action potentials. Stimulation is done unilaterally on the dorsolateral prefrontal cortex and tDCS will be done for the patients during 5 consecutive days, before tDCS, neuropsychiatric tests including frontal assessment battery,  trail making test , verbal fluency (PFT), Picture naming task (PNT), Go no-GO task (GGT),Brief test  and NPI (Neuropsychiatric inventory) are performed for patients immediately after tDCS and again 1 month after tDCS. Patients will undergo a second round 2 months after the first tDCS, and those who received anodal at the beginning will now receive sham and vice versa.</i_keyword>
      <i_keyword>Control group: After confirming the diagnosis of the patients, the MMSE Mental State Examination-Mini test is taken from the people. The short MMSE mental state test is a test to evaluate the quality of consciousness with the diagnosis and screening of dementia, the maximum score of which is 30. People whose MMSE score is above 20 are included in the study. Patients are treated with anodal tDCS and sham tDCS. The sham group is a general term to indicate a passive form of stimulation (eg, very brief or weak) that is used in research to control the placebo effect. Stimulation is performed unilaterally on the dorsolateral prefrontal cortex and tDCS will be performed for 5 consecutive days for the patients. Before performing tDCS, neuropsychiatric tests including frontal battery assessment,rail makimg test ,phonemic verbal fluency (PFT) ), Picture naming task (PNT), Go no-GO task (GGT), Brief test and NPI (Neuropsychiatric inventory) are performed for patients immediately after tDCS and again 1 month after tDCS. Patients will undergo a second round 2 months after the first tDCS, and those who received anodal at the beginning will now receive sham and vice versa.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Language. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: verbal fluency test questionnaire /frontal assesment battery questionnaire/ picture naming task questionnaire /neuropsychiatric inventory questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Psychiatric manifestation. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: neuropsychiatricinventory-questionnaire.</sec_outcome>
      <sec_outcome>Behavior. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: neuropsychiatricinventory-questionnaire.</sec_outcome>
      <sec_outcome>Executive function. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: frontal assesment battery/ trail making test/ behavior rating inventory of executive function.</sec_outcome>
      <sec_outcome>Response inhibition. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: go /no go task interview.</sec_outcome>
      <sec_outcome>Impulsiviness. Timepoint: The beginning of the study / after 5 tdcs sessions / one month later / the end of the study. Method of measurement: go /no go task interview.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-03</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Central building of Shiraz University of Medical Sciences, Zand Street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
